• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 425 filed by Pieris Pharmaceuticals Inc.

    12/12/24 4:15:29 PM ET
    $PIRS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PIRS alert in real time by email
    425 1 pirs20241212c_425.htm FORM 425 pirs20241212c_425.htm

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     


    FORM 8-K


     

    CURRENT REPORT

    Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): December 11, 2024


     

    PIERIS PHARMACEUTICALS, INC.

    (Exact name of registrant as specified in its charter)

     


     

    Nevada

    001-37471

    30-0784346

    (State or other jurisdiction of
    Incorporation)

    (Commission
    File Number)

    (IRS Employer
    Identification No.)

     

    225 Franklin Street, 26th Floor

    02110

    Boston, MA

     

    (Address of principal executive offices)

    (Zip Code)

     

    s telephone number, including area code: 857-246-8998

    N/A

    (Former name or former address, if changed since last report.)


     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

     

    ☒

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading Symbol(s)

     

    Name of each exchange on which registered

    Common Stock, $0.001 par value per share

     

    PIRS

     

    The Nasdaq Capital Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

     

    Emerging Growth Company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

     

     

     

     

    Item 3.03 Material Modification to Rights of Security Holders.

     

    On December 11, 2024, Pieris Pharmaceuticals, Inc. (“Pieris” or the “Company”) held a special meeting of its stockholders (the “Special Meeting”) at which the Company’s stockholders considered and adopted the proposals outlined in the definitive proxy statement/prospectus statement, dated November 8, 2024 (the “Proxy Statement”), and filed by the Company with the Securities and Exchange Commission (the “SEC”) on November 8, 2024. At the Special Meeting, the Company’s stockholders approved an amendment to the amended and restated articles of incorporation of the Company (the “Authorized Share Increase Amendment”) to implement an increase in the number of authorized shares of common stock from 3,750,000 to 200,000,000 (the “Share Increase”). On December 12, 2024, the Company filed the Share Increase Amendment with the Nevada Secretary of State to effect the Share Increase effective on December 12, 2024. As a result of the Share Increase, the number of  authorized shares of the Company’s common stock was increased from 3,750,000 to 200,000,000 shares. The foregoing description of the Authorized Share Increase Amendment does not purport to be complete and is subject to, and qualified by, the full text of such document, a copy of which is filed as Exhibit 3.1 hereto and is incorporated by reference herein.

     

    On December 12, 2024, the Company redeemed the Series F Preferred Stock automatically following the effectiveness of the Share Increase, as further described in Item 5.07 of this Current Report on Form 8-K. As a result of the redemption, the holder of the Series F Preferred Stock received consideration of $0.01 in cash. Following the effectiveness of such redemption upon the effectiveness of the Share Increase, on December 12, 2024, the Company filed a Certificate of Withdrawal with the Nevada Secretary of State to withdraw the Certificate of Designation relating to the Series F Preferred Stock. The foregoing description of the Certificate of Withdrawal does not purport to be complete and is subject to, and qualified by, the full text of such document, a copy of which is filed as Exhibit 3.2 hereto and is incorporated by reference herein.

     

     

     

     

    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    (e) At the Special Meeting, the Company’s stockholders approved the Palvella Therapeutics, Inc. 2024 Equity Incentive Plan (the “2024 EIP”), which was previously approved and adopted by the Board of Directors of the Company on September 12, 2024, subject to stockholder approval, and became effective upon the receipt of stockholder approval at the Special Meeting.

     

    A description of the terms and conditions of the 2024 EIP is set forth on pages 211-216 in the Proxy Statement under the heading “Proposal No. 3: Approval of the 2024 Equity Incentive Plan” and is incorporated herein by reference. Such description is qualified in its entirety by reference to the actual terms of the 2024 EIP, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

     

     

     

     

    Item 5.03.  Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

     

    To the extent required by Item 5.03 of Form 8-K, the information contained in Item 3.03 of this Current Report on Form 8-K is incorporated by reference herein.

     

     

     

     

    Item 5.07 Submission of Matters to a Vote of Security Holders.

     

    (a) On December 11, 2024, the Company held the Special Meeting. As of October 28, 2024, the record date for the Special Meeting, 1,320,240 shares of the Company’s common stock (each entitled to one vote per share) and one share of the Company’s Series F Preferred Stock (entitled to 25,000,000 votes per share on solely on the Authorized Share Increase Amendment proposal (“Proposal No. 2”)) were issued and outstanding. The Series F Preferred Stock entitles and requires the holder thereof to (i) vote together with the holders of the Company’s common stock on Proposal No. 2 and (ii) cast, in person or by proxy, the 25,000,000 votes of the Series F Preferred Stock on Proposal No. 2 in a manner that is proportionate to the manner in which all shares of the Company’s common stock are voted FOR or AGAINST Proposal No. 2, excluding any shares of common stock that are not voted “FOR” or “AGAINST” such proposal for any reason, including, without limitation, any abstentions or broker non-votes. A quorum of 1,018,071 shares of common stock, comprising 77.11% of the outstanding shares of common stock, and one share of Series F Preferred Stock, comprising 100% of the outstanding shares of Series F Preferred Stock, were present in person or by proxy at the Special Meeting.

     

    (b) At the Special Meeting, the Company’s stockholders voted on the proposals set forth below relating to the Agreement and Plan of Merger, dated as of July 23, 2024 (the “Merger Agreement”), by and between the Company, Polo Merger Sub, Inc. (the “Merger Sub”), a Delaware corporation and a wholly owned subsidiary of the Company, and Palvella Therapeutics, Inc., a Delaware corporation (“Palvella”), whereby Merger Sub will merge with and into Palvella, with Palvella continuing as a wholly-owned subsidiary of the Company and the surviving corporation of the merger (the "Merger"). The proposals are described in detail in the Proxy Statement (as amended or supplemented thereafter) and first mailed to the Company’s stockholders on or about November 8, 2024. The number of votes cast in favor or against by the stockholders and, where applicable, the number of abstentions and the number of broker non-votes on each of the foregoing matters are set forth below.

     

    Proposal No. 1: Approval of the Issuance of Shares of Pieris Common Stock Pursuant to the Terms of the Merger Agreement and the Purchase Agreement for Purposes of Nasdaq Listing Rules 5635(a), (b) and (d).

     

    This proposal was approved by the requisite vote of the holders of the Company’s common stock.

     

    For Against Abstain  Broker Non-Votes
    718,345 4,199 637 294,890

     

     

    Proposal No. 2: Approval of an amendment to the Amended and Restated Articles of Incorporation of Pieris to Increase the Number of Authorized Shares of Pieris Common Stock.

     

    This proposal was approved by the requisite vote of the holders of the Company’s common stock and Series F Preferred Stock.

     

    For Against Abstain  Broker Non-Votes
    25,400,549 322,372 260 294,890

     

    Of the total 1,320,240 votes eligible to be cast by the holders of the Company’s common stock entitled to vote on Proposal No. 2, 713,861 votes were cast FOR Proposal No. 2 and 9,060 votes were cast AGAINST Proposal No. 2. Of the total 25,000,000 votes eligible to be cast by the holders of the Series F Preferred Stock entitled to vote on Proposal No. 2, 24,686,688 votes were cast FOR Proposal No. 2 and 313,312 votes were cast AGAINST Proposal No. 2, in proportion to the votes cast FOR and AGAINST Proposal No. 2 by the holders of the Company’s common stock. As a result, of the total 26,320,240 votes eligible to be cast by the holders of the Company’s common stock and Series F Preferred Stock entitled to vote on Proposal No. 2, 25,400,549 votes were cast FOR Proposal No. 2 and 322,372 votes were cast AGAINST Proposal No. 2. 

     

    Proposal No. 3: Approval of the 2024 Equity Incentive Plan

     

    This proposal was approved by the requisite vote of the holders of the Company’s common stock.

     

    For Against Abstain  Broker Non-Votes
    685,017 37,460 704 294,890

     

    Proposal No. 4: Ratification of the Pieris Board of Directors' Approval of an Amendment to the Amended and Restated Articles of Incorporation of Pieris to Change the Name of the Corporation from "Pieris Pharmaceuticals, Inc." to "Palvella Therapeutics, Inc."  

     

    This proposal was approved by the requisite vote of the holders of the Company’s common stock.

     

    For Against Abstain  Broker Non-Votes
    1,010,735 4,337 2,999 -

     

    Proposal No. 5: Approval of Possible Adjournment of the Pieris Special Meeting  

     

    This proposal was approved by the requisite vote of the holders of the Company’s common stock, but an adjournment was unnecessary because there was a quorum present and there were sufficient votes received at the time of the Special Meeting to approve Proposal Nos. 1 and 2.

     

    For Against Abstain  Broker Non-Votes
    994,242 23,418 411 -

     

     

     

     

    Item 8.01 Other Events.

     

    The closing of the Merger is expected to occur on December 13, 2024, assuming the satisfaction or waiver of all conditions under the Merger Agreement.  As previously disclosed, the Company will enter into a Contingent Value Rights Agreement with a rights agent, pursuant to which the Company’s pre-Merger capital stockholders of record on December 12, 2024 will receive one contingent value right for each outstanding share of the Company’s common stock held by such stockholder, or share of common stock underlying any preferred stocks held by such stockholder.

     

     

     

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    3.1 Certificate of Amendment to the Company’s Amended and Restated Articles of Incorporation, dated December 12, 2024
       
    3.2 Certificate of Withdrawal of the Series F Preferred Stock, dated December 12, 2024
       
    10.1 Palvella Therapeutics, Inc.'s 2024 Equity Incentive Plan
       

    104

    Cover Page Interactive Data File (embedded within the Inline XBRL document).

     

     

     

     

    Cautionary Note Regarding Forward-Looking Statements

     

    This Form 8-K contains forward-looking statements including within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended, (the "Exchange Act") Section 27A of the Securities Act of 1933, as amended, (the "Securities Act") and the Private Securities Litigation Reform Act of 1995 (“PSLRA”). This includes statements regarding: the anticipated completion and effects of the proposed Merger and private placement; anticipated communications regarding each of Pieris’ and Palvella’s entry into the Merger Agreement; and other statements regarding management’s intentions, plans, beliefs, expectations or forecasts for the future, and, therefore, you are cautioned not to place undue reliance on them. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Pieris uses words such as “anticipates,” “believes,” “plans,” “expects,” “projects,” “future,” “intends,” “may,” “will,” “should,” “could,” “estimates,” “predicts,” “potential,” “continue,” “guidance,” and similar expressions to identify these forward-looking statements that are intended to be covered by the safe-harbor provisions of the PSLRA, the Securities Act, or the Exchange Act. Such forward-looking statements are based on Pieris’ expectations and involve risks and uncertainties; consequently, actual results may differ materially from those expressed or implied in the statements due to a number of factors, including, but not limited to, risks relating to: the risks related to the proposed Merger included in the Registration Statement, the completion of the Merger, including the need for stockholder approval and the satisfaction (or waiver) of closing conditions; and the occurrence of any event, change or other circumstance or condition that could give rise to the termination of the Merger Agreement.

     

    New factors emerge from time to time, and it is not possible for Pieris to predict all such factors, nor can Pieris assess the impact of each such factor on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. These risks, as well as other risks associated with the Merger, are more fully discussed in the proxy statement/prospectus filed with the SEC in connection with the contemplated transactions. Additional risks and uncertainties are identified and discussed in the “Risk Factors” section of Pieris’ Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other documents filed from time to time with the SEC. Forward-looking statements included in this Form 8-K are based on information available to Pieris as of the date of this Form 8-K. Pieris undertakes no obligation to update such forward-looking statements to reflect events or circumstances after the date of this Form 8-K, except to the extent required by law.

     

    No Offer or Solicitation

     

    This Form 8-K is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the potential transaction and shall neither constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which the offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act or an exemption therefrom.

     

     

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

    PIERIS PHARMACEUTICALS, INC.

       

    Dated: December 12, 2024

    /s/ Tom Bures

     

    Tom Bures

     

    Chief Financial Officer

     

     

     

     
    Get the next $PIRS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PIRS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PIRS
    Leadership Updates

    Live Leadership Updates

    See more
    • Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer

      WAYNE, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies, today announced the appointment of Matthew E. Korenberg as Chief Financial Officer, effective immediately. Mr. Korenberg is a seasoned operational and financial leader with more than 27 years of senior executive experience in biotech companies and healthcare investment banking. Throughout his career, he has focused on capital raising, partnering and licensing deals, acquisitions, as well as overseeing p

      10/17/24 7:30:00 AM ET
      $LFCR
      $LGND
      $PIRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Avacta Announces the Appointment of Darlene Deptula-Hicks as Non-Executive Director of the Board of Directors

      Avacta Group plc Avacta Announces the Appointment of Darlene Deptula-Hicks as Non-Executive Director of the Board of Directors London, England; July 8, 2024; Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted cancer treatments and powerful diagnostics, today announced the appointment of Darlene Deptula-Hicks, MBA as a Non-Executive Director of the Company's Board of Directors, effective 26 June 2024. Ms. Deptula-Hicks is a highly accomplished financial executive with decades of experience working with and advising private and public life sciences companies. Shaun Chilton, Chairman of the Board of Avacta, commented: "Avacta is at a pivotal time in its e

      7/8/24 8:15:00 AM ET
      $PIRS
      $TTOO
      $FSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
    • OMass Therapeutics Announces Appointment of New Board Chair and Series B Extension

      PRESS RELEASE OMass Therapeutics Announces Appointment of New Board Chairand Series B Extension Jim Geraghty joins as Independent Director and Chair, bringing US and international experience from Genzyme and as NED and chair of multiple listed biotechsBritish Patient Capital invests £10 million in a Series B extension bringing total raised in this round to £85.5 million Oxford, United Kingdom – 15 May 2023 – OMass Therapeutics (‘OMass', or ‘the Company'), a biotechnology company that identifies medicines against highly validated target ecosystems, today announces the appointment of Jim Geraghty as chairman of its board of directors and an additional investment of £10 million from new inve

      5/15/23 2:00:00 AM ET
      $FULC
      $ORTX
      $PIRS
      $VYGR
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $PIRS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Pieris Pharmaceuticals Inc.

      SC 13G/A - PALVELLA THERAPEUTICS, INC. (0001583648) (Subject)

      12/17/24 5:42:35 PM ET
      $PIRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Pieris Pharmaceuticals Inc.

      SC 13G/A - PIERIS PHARMACEUTICALS, INC. (0001583648) (Subject)

      11/14/24 9:07:46 AM ET
      $PIRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Pieris Pharmaceuticals Inc.

      SC 13G - PIERIS PHARMACEUTICALS, INC. (0001583648) (Subject)

      8/1/24 8:00:08 AM ET
      $PIRS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PIRS
    SEC Filings

    See more
    • Pieris Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Change in Shell Company Status, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics, Other Events, Financial Statements and Exhibits

      8-K - PALVELLA THERAPEUTICS, INC. (0001583648) (Filer)

      12/13/24 9:53:05 PM ET
      $PIRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 425 filed by Pieris Pharmaceuticals Inc.

      425 - PIERIS PHARMACEUTICALS, INC. (0001583648) (Subject)

      12/12/24 4:15:29 PM ET
      $PIRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pieris Pharmaceuticals Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Submission of Matters to a Vote of Security Holders, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits

      8-K - PIERIS PHARMACEUTICALS, INC. (0001583648) (Filer)

      12/12/24 4:15:03 PM ET
      $PIRS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PIRS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Heron Elaine J

      4 - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)

      12/17/24 8:46:08 PM ET
      $PIRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Wessel Tadd S.

      4 - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)

      12/17/24 8:45:10 PM ET
      $PIRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Davis Todd C

      4 - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)

      12/17/24 8:44:40 PM ET
      $PIRS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PIRS
    Financials

    Live finance-specific insights

    See more

    $PIRS
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $PIRS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Ligand Reports Second Quarter 2024 Financial Results

      Conference call at 4:30 p.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and six months ended June 30, 2024, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 4:30 p.m. Eastern Time to discuss this announcement and answer questions. "We had a strong quarter and are on track to meet the long-term growth objectives we outlined in December," said Todd Davis, CEO of Ligand. "We added four new commercial-stage programs in the first half of this year, including QARZIBA®, an orphan oncology product we acquired following the APEIRON Biologics transacti

      8/6/24 4:01:00 PM ET
      $AGEN
      $AMGN
      $CASI
      $LGND
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement

      Proposed merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for serious, rare genetic skin diseases for which there are no FDA-approved therapiesCombined company is expected to have approximately $80.5 million of cash and cash equivalents at closing, including approximately $78.9 million from an oversubscribed private financing with participation from a syndicate of leading healthcare-dedicated investors, which is expected to provide cash runway into the second half of 2027Anticipated cash and cash equivalents are expected to fund combined company through multiple clinical trial milestones, including pivotal P

      7/24/24 6:30:00 AM ET
      $LGND
      $PIRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pieris Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Updates

      COMPANY TO HOST AN INVESTOR CONFERENCE CALL TODAY, WEDNESDAY, MAY 10, 2023, AT 8:00 AM EDTEnrollment for elarekibep (PRS-060/AZD1402) Phase 2a study for asthma continues to progress with topline clinical data anticipated by mid-2024; successful safety review completed for 10 mg dose cohortPRS-220, inhaled Anticalin protein for idiopathic pulmonary fibrosis (IPF), continues in Phase 1 study with topline results expected H2 2023PRS-400, inhaled Anticalin protein for muco-obstructive respiratory disease, advances toward anticipated development candidate nomination H2 2023New preclinical data to be presented at the American Thoracic Society (ATS) 2023 International Conference in May 2023 for bot

      5/10/23 7:00:00 AM ET
      $PIRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Palvella Therapeutics Announces First Patient Dosed in SELVA Phase 3 Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations

      Phase 3 single-arm, baseline-controlled trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for the treatment of microcystic lymphatic malformations (microcystic LMs) currently enrolling participants at leading vascular anomaly centers across the U.S. Microcystic LMs is a chronically debilitating and lifelong genetic disease affecting an estimated more than 30,000 diagnosed patients in the U.S. QTORIN™ rapamycin has the potential to be the first approved therapy and standard of care in the U.S. for microcystic LMs WAYNE, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on develop

      11/7/24 8:30:00 AM ET
      $PIRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer

      WAYNE, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies, today announced the appointment of Matthew E. Korenberg as Chief Financial Officer, effective immediately. Mr. Korenberg is a seasoned operational and financial leader with more than 27 years of senior executive experience in biotech companies and healthcare investment banking. Throughout his career, he has focused on capital raising, partnering and licensing deals, acquisitions, as well as overseeing p

      10/17/24 7:30:00 AM ET
      $LFCR
      $LGND
      $PIRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Palvella Therapeutics Announces Presentations at the 12th Pediatric Dermatology Research Alliance (PeDRA) Annual Conference

      WAYNE, PA., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies, today announced two poster presentations at the upcoming 12th Pediatric Dermatology Research Alliance (PeDRA) Annual Conference, taking place October 24-26, 2024, in Phoenix, AZ. The presentations include data supporting QTORIN™ rapamycin 3.9% anhydrous gel (QTORIN™ rapamycin) as a potential targeted therapy for microcystic lymphatic malformations (microcystic LMs) and a review of the Phase 3 SELVA

      10/15/24 7:30:00 AM ET
      $PIRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Geraghty James A bought $1 worth of Series F Preferred Stock (1 units at $1.00) (SEC Form 4)

      4 - PIERIS PHARMACEUTICALS, INC. (0001583648) (Issuer)

      10/28/24 5:18:29 PM ET
      $PIRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Adar1 Capital Management, Llc bought $92,326 worth of shares (6,000 units at $15.39) (SEC Form 4)

      4 - PIERIS PHARMACEUTICALS, INC. (0001583648) (Issuer)

      8/12/24 6:48:13 PM ET
      $PIRS
      Biotechnology: Pharmaceutical Preparations
      Health Care